Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12249038 | 0.92 | ANPEP (0.44) | CA12CA2CA4CA6CA5A | |
| SCHEMBL20243390 | 0.88 | CA12 (0.52) | CA12CA2CA4CA6CA5A | |
| SCHEMBL9079828 | 0.88 | ALDH1A1 (0.39) | CA12CA2CA4CA6CA5A | |
| SCHEMBL753089 | 0.88 | ALDH1A1 (0.39) | CA12CA2CA4CA6CA5A | |
| SCHEMBL9079391 | 0.88 | ALDH1A1 (0.39) | CA12CA2CA4CA6CA5A | |
| SCHEMBL9043256 | 0.88 | ALDH1A1 (0.39) | CA12CA2CA4CA6CA5A | |
| SCHEMBL9425876 | 0.88 | ALDH1A1 (0.39) | CA12CA2CA4CA6CA5A | |
| SCHEMBL2528294 | 0.87 | — | — | |
| SCHEMBL3126491 | 0.87 | — | — | |
| SCHEMBL2336707 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170056526-A1 | COMPOSITIONS FOR GASTROINTESTINAL ADMINISTRATION OF RNA | ETHRIS GMBH (DE) | 2017-03-02 | — | — | US | disclosed |
| EP-1812074-B1 | INTRACELLULAR PEPTIDE DELIVERY | NITTO DENKO CORP (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-7521415-B2 | pretreatment of the cells with polycations, cationic polymers and/or cationic peptides, then administering the peptides to the pretreated cells and transporting the peptide into the pretreated mammalian cells | NITTO DENKO CORPORATION (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1812074-A1 | INTRACELLULAR PEPTIDE DELIVERY | Nitto Denko Corporation (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1675888-B1 | CATIONIC POLYMERS HAVING DEGRADABLE CROSSLINKS | NITTO DENKO CORP (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-7163677-B2 | Cationic polymers having degradable crosslinks | NITTO DENKO CORPORATION (JP) | 2007-01-16 | — | — | US | disclosed |
| EP-1675888-A1 | CATIONIC POLYMERS HAVING DEGRADABLE CROSSLINKS | Nitto Denko Corporation (JP) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006044986-A1 | INTRACELLULAR PEPTIDE DELIVERY | NITTO DENKO CORPORATION (JP) | 2006-04-27 | — | — | WO | disclosed |
| US-20060083737-A1 | pretreatment of the cells with polycations, cationic polymers and/or cationic peptides, then administering the peptides to the pretreated cells and transporting the peptide into the pretreated mammalian cells | NITTO DENKO CORPORATION (JP) | 2006-04-20 | — | — | US | disclosed |
| WO-2005042620-A1 | CATIONIC POLYMERS HAVING DEGRADABLE CROSSLINKS | NITTO DENKO CORPORATION (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-20050089503-A1 | Cationic polymers having degradable crosslinks | NITTO DENKO CORPORATION (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-0729938-B1 | A method for producing aryl alkyl hydroperoxides | MITSUI CHEMICALS INC (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-6028193-A | CATALYZING THE OXIDATION REACTION IN PRESENCE OF A TRANSITION METAL COMPLEX WHICH CONTAINS A CYCLIC POLYFUNCTIONAL AMINE COMPOUND HAVING AT LEAST THREE NITROGEN ATOMS IN THE RING FORMING MOLECULAR | MITSUI CHEMICALS, INC. (JP) | 2000-02-22 | — | — | US | disclosed |
| US-5945572-A | Method for producing aryl alkyl hydroperoxides | MITSUI CHEMICALS, INC. (JP) | 1999-08-31 | — | — | US | disclosed |
| US-5847227-A | Method for producing aryl alkyl hydroperoxides | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-08 | — | — | US | disclosed |
| EP-0729938-A2 | A method for producing aryl alkyl hydroperoxides | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-04 | — | — | EP | disclosed |
| US-4018946-A | Production of heat-expandable styrene-polymer bit-pieces | SEALED AIR CORPORATION (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056526-A1 | COMPOSITIONS FOR GASTROINTESTINAL ADMINISTRATION OF RNA | RNASE1, RNMT, EXOSC9 | CA12 3281/4885CA2 4070/4885CA4 3172/4885 |
| US-20050089503-A1 | Cationic polymers having degradable crosslinks | HNRNPH3, FIBP, PUF60 | CA12 793/4885CA2 1313/4885CA4 1517/4885 |
| US-20060083737-A1 | pretreatment of the cells with polycations, cationic polymers and/or cationic peptides, then administering the peptides to the pretreated cells and transporting the peptide into the pretreated mammalian cells | TAP1, PRCP, TAP2 | CA12 2081/4885CA2 2477/4885CA4 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.